Scope and US Patent 9,089,496 Claim-Chart Analysis: methylphenidate ion-exchange resin triggered delayed release (pH-triggered + diffusion barrier) for ADHD
US Drug Patent 9,089,496 is centered on an oral methylphenidate formulation built from ion-exchange resin–complexed drug-resin particles in a two-population particle system: (i) an immediate-release fraction and (ii) a triggered delayed-release fraction that uses a pH-triggered coating over a diffusion barrier coating. The independent claim (claim 1) and its dependent set lock in (a) the drug-resin particle architecture, (b) the trigger mechanism and materials, (c) quantitative drug loading split across fractions, and (d) in vivo pharmacokinetic profile similarity targets, with additional dependent claims specifying specific dissolution assay conditions and numerical PK windows in adults with ADHD.
Core claim architecture (what must be present to practice the claims)
Independent claim 1 requires, in combination:
- A pharmaceutical composition for ADHD where the active is methylphenidate.
- Methylphenidate is complexed with ion-exchange resin particles to form drug-resin particles.
- Two distinct populations in the composition:
- First plurality: provides immediate release.
- Second plurality: provides delayed release using:
- a triggered-release coating triggered by pH change, and
- a diffusion barrier coating.
- Quantitative split:
- 20–30 wt% methylphenidate in the immediate-release fraction
- 70–80 wt% methylphenidate in the delayed-release fraction
- PK equivalence/similarity:
- Administration to humans produces a mean concentration-time profile for d-methylphenidate with one or more parameters (AUC and/or Cmax/Tmax windows across multiple time ranges) substantially similar to those of at least one serum profile shown in FIG. 20A.
Dependent claims then narrow the independent concept by:
- Selecting coating chemistries for the triggered layer (claim 2).
- Selecting diffusion barrier material (claims 3-4, 6).
- Defining coating stack order (claims 5-6).
- Selecting specific strong acidic cation exchange resins (claim 7).
- Fixing the wt% split at about 25/75 (claim 8).
- Constraining dosage form categories (claim 9) and dose range (claim 10).
- Binding dissolution performance to a specific USP apparatus 2 assay and pH step (claim 11).
- Tying PK similarity to additional figures (claim 12).
- Providing equivalence to doses in mg of methylphenidate HCl (claims 13-17).
- Using adult ADHD PK numeric ranges and confidence-interval conditions (claims 14-18).
- Scaling PK numeric windows to an about-60 mg total dose (claims 19-22).
What is the claim scope of US 9,089,496? (independent claim 1 and protected technical subject matter)
Claim 1 covers a formulation rather than a single polymer or a single PK endpoint. The scope is best understood as an assembly claim with functional + compositional + quantitative + PK-similarity limitations.
Key scope levers that define infringement risk
-
Resin-complexed methylphenidate
- Practice must use ion-exchange resin particles with methylphenidate complexed to form drug-resin particles.
- Use of a different drug-carrier approach (e.g., matrix tablets, polymeric nanoparticles without ion-exchange complexation) falls outside.
-
Two-population particle system
- Must include both:
- an immediate-release particle fraction, and
- a delayed-release particle fraction with specific coating logic.
- If an accused product uses only one coated population or a single continuous release mechanism, it is outside.
-
pH-triggered coating + diffusion barrier
- Delayed-release particles must have:
- a triggered-release coating that is triggered by a pH change, and
- a diffusion barrier coating beneath/associated with that triggered layer.
- If the delayed-release mechanism is time-based rather than pH-triggered, or if it lacks a diffusion barrier layer, scope tightens against the patentee.
-
Quantitative drug loading split (20–30 / 70–80 wt%)
- The resin loading must split across populations in the claimed ranges.
- Products that tune release using different ratios (e.g., narrower than claimed, or reversed split) can avoid all dependent narrowing but still may hit claim 1 if within range.
-
PK “substantially similar” requirement tied to FIG. 20A
- This is a high-stakes claim feature because it connects the formulation to an in vivo performance target for d-methylphenidate.
- “Substantially similar” can be litigated via expert interpretation and statistical equivalence/overlap of PK metrics.
What claim 19 does relative to claim 1
Claim 19 is an independent claim but is structured differently: it adds a more numeric PK envelope for total methylphenidate:
- For a total methylphenidate dose equivalent to ~60 mg methylphenidate HCl, it requires AUC0-∞ of about 160 to 180 ng·hr/mL.
This creates a second infringement pathway that is less about FIG-based “substantially similar” and more about a numeric AUC window.
Which coatings, resins, and coating stacks are explicitly claimed? (triggered-release and diffusion barrier materials)
Claim 2 (triggered-release coating options) limits the pH-triggered coating to enumerated materials or mixtures, including:
- cellulose acetate phthalate
- cellulose acetate trimellitate
- hydroxypropyl methylcellulose phthalate
- polyvinyl acetate phthalate
- carboxymethylethylcellulose
- copolymerized methacrylic acid/methacrylic acid methyl esters
- copolymerized methacrylic acid/acrylic acid ethyl esters
- mixtures
Claim 3 (diffusion barrier coating) requires a water insoluble, water permeable membrane.
Claim 4 and claim 6 (ethylcellulose) specifically narrow the membrane to ethylcellulose.
Claim 5 (stack order) requires the triggered-release coating covers the diffusion barrier coating.
Claim 7 (strong acidic cation exchange resins) enumerates:
- polistirex
- polacrilex
- cholestyramine
- polacrilin
- mixtures
Claim 8 locks the wt% split to:
- about 25 wt% in immediate-release drug-resin particles
- about 75 wt% in delayed-release, coated drug-resin particles
Litigation meaning of these lists: If an accused product uses a different trigger polymer than the listed set, it can potentially avoid dependent claims 2 (and 14-like claim subsets) while still risking claim 1 depending on how strictly “triggered-release coating” is interpreted and whether substitute coatings are found to fall within “triggered-release” as a functional limitation. The dependent enumeration is a strong narrowing feature for validity and design-around.
How do the dissolution and in vivo PK limits constrain the protected formulations? (assay conditions, time windows, and statistical similarity)
Dissolution test is claimed with assay specificity (claim 11)
Claim 11 requires an in vitro dissolution profile under:
- Initial dissolution medium: 0.1 N HCl
- after 2 hours: medium adjusted to pH ~6.8
- USP Apparatus 2
- and release thresholds for methylphenidate (by weight) at timepoints:
- 30–33% released within first 30 minutes
- 34–42% released within 2 hours
- 40–80% released within 4 hours
- 80–100% released within 24 hours
This is a classic “performance plus method” constraint that can be used to argue equivalence in formulation similarity, but it can also provide a direct defense if an accused product’s dissolution under the same conditions does not meet these bands.
PK similarity tied to figures and specific endpoints (claims 1, 12, 14–18, 19–22)
- Claim 1: d-methylphenidate PK metrics substantially similar to profiles in FIG. 20A; metrics can include AUC0-3, AUC0-5, AUC0-Tmax, AUC5-12, AUC5-24, AUC/Tmax-related variants, AUC5-t, AUC0-24, AUC0-∞.
- Claim 12: PK similarity to profiles in FIGS. 27A, 27B, 28A, 28B.
- Claims 14–17: orally disintegrating tablet form with explicit mean plasma PK numeric windows for adults with ADHD at an overall exposure scaled from a “total methylphenidate dose equivalent to a 60 mg total dose of methylphenidate hydrochloride.”
- These specify AUC0-3, AUC0-5, AUC5-24, AUC0-24 along with d/l/total values and their ±20%/+25% ranges for mean parameters, and a fixed Cmax for d- and l-fractions (d: 20.17 ng/mL; l: 0.44 ng/mL; total: 20.60 ng/mL).
- Claim 18: statistical similarity using a 90% confidence interval upper/lower bounds within 90% to 415% of the bioequivalent reference value (as written in the claim text).
Claim 19 adds:
- AUC0-∞ for total methylphenidate: about 160–180 ng·hr/mL at ~60 mg total dose equivalent.
Claims 20–22 further specify:
- Claim 20: mean Cmax greater than 16.55 ng/mL.
- Claim 21: Tmax approximately 6 hours.
- Claim 22: bimodal profile with two peaks; first peak around 3 hours.
Risk implication: Products that are chemically similar but shift PK profile outside the claimed numeric windows can potentially avoid the independent numeric claim 19 and dependent numeric PK claims, but may still face claim 1’s “substantially similar” language depending on FIG-based benchmarks and expert statistical analysis.
How broad is US 9,089,496 across dosage forms and dose levels? (form factor and dose limitations)
Claim 9 includes multiple dosage forms:
- liquid suspension
- chewable composition
- orally disintegrating tablet composition
Claim 10 sets an amount constraint:
- 10–60 mg methylphenidate per claimed composition.
Claims 14–18 appear focused on orally disintegrating tablets, using adult ADHD PK parameters.
Claims 19–22 focus on a total methylphenidate dose equivalent to about 60 mg methylphenidate HCl and associated PK metrics.
Scope is therefore not confined to a single branded dosage form; the patent family (as captured by these claims) is trying to protect the technology platform and key performance outcomes across oral presentations.
What is protectable vs easy to design around? (practical boundary conditions from the claim text)
Strong “must-have” elements likely central to validity and infringement
- Ion-exchange resin complexation of methylphenidate to form drug-resin particles.
- Two particle populations with differing release behavior.
- pH-triggered coating on delayed-release particles and presence of a diffusion barrier.
- Specified wt% split of methylphenidate between immediate and delayed particle populations (20–30 / 70–80).
- PK performance alignment to the claimed metrics.
Common design-around pathways suggested by the claim language
- Replace pH-triggered triggered-release coatings with a mechanism not keyed to pH change (or remove pH-triggered layer function).
- Remove or change the diffusion barrier layer to a different release mechanism not requiring water insoluble, water permeable membrane behavior.
- Use different resin chemistry that does not fall within strong acidic cation exchange resins as enumerated (dependent claim 7) and, if needed, also avoid the claimed resin type at the independent level by not forming drug-resin particles via the required ion-exchange resin system.
- Shift formulation drug-loading split outside the 20–30 and 70–80 wt% bands.
- For products aimed at the delayed-release PK profile, shift exposure or Cmax/Tmax so numeric limits in claims 19–22 are not met.
Patent estate analysis beyond the provided claim text (why a full US landscape is not computable here)
A “detailed analysis of the scope and claims and patent landscape” for US 9,089,496 requires at minimum:
- the patent’s filing date, priority dates, current legal status, expiration, and maintenance history,
- the full specification to interpret FIG. 20A/27A/28A/28B and “substantially similar,”
- prosecution history and claim amendments,
- related continuations/divisionals and other family members,
- and the Orange Book / FDA reference product and listed patents, plus Paragraph IV/biosimilar/generic litigation.
Those facts are not present in the input. Under the operating constraints, no additional landscape can be produced without risking inaccuracy.
Key Takeaways
- US 9,089,496 is an oral methylphenidate ADHD formulation patent centered on ion-exchange resin–complexed drug-resin particles in a two-population architecture: immediate-release plus pH-triggered delayed release using a trigger coating over a diffusion barrier.
- The strongest claim scope determinants are the drug loading split (20–30 wt% immediate / 70–80 wt% delayed), the coating stack logic, the specific enumerated coating chemistries (dependent claims), and the in vivo PK similarity/numeric windows (claims 1, 12, 14–18, 19–22).
- Dependent claims tightly narrow materials: trigger coating options and ethylcellulose diffusion barrier, plus strong acidic cation exchange resins (polistirex/polacrilex/cholestyramine/polacrilin).
- For enforcement or design-around, the fastest technical screening is: (1) confirm resin-complexed particles and the two-population system, (2) confirm pH-triggered and diffusion barrier coatings and their stack, (3) measure wt% split, and (4) compare dissolution and adult ADHD PK endpoints against the specific numeric bands.
FAQs
1) What does “triggered-release coating triggered by a pH change” require under US 9,089,496?
It requires delayed-release particle coatings whose release mechanism is keyed to a pH change, not purely time-based release. The dependent claims also list specific pH-responsive polymer classes.
2) Does US 9,089,496 cover only orally disintegrating tablets?
No. Claim 9 includes liquid suspension and chewable forms as well as orally disintegrating tablets, though certain numerical PK-dependent claims are drafted for orally disintegrating tablets.
3) Can a product avoid the patent by changing the diffusion barrier polymer away from ethylcellulose?
It can avoid dependent claims 4 and 6 that explicitly require ethylcellulose, but it still risks the broader independent structure in claim 1 unless the product also avoids the required diffusion barrier concept and related coating architecture.
4) How important is the 20–30 wt% / 70–80 wt% methylphenidate split?
It is a core element of claim 1’s formulation definition. Moving outside the bands is a direct pathway to non-infringement of claim 1 (and claim 8).
5) What is the most litigation-relevant numerical in vivo target in the provided claim set?
The clearest numeric target is in claim 19: total methylphenidate AUC0-∞ about 160–180 ng·hr/mL at a dose equivalent to ~60 mg methylphenidate HCl, plus additional numeric constraints on Cmax, Tmax, and bimodality in claims 20–22.
